Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction

Journal of Alzheimer s Disease(2024)10.3233/jad-240063Source: DataRank Database

The 5HT2b Receptor in Alzheimer’s Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction is a research paper published in Journal of Alzheimer s Disease (2024). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.23)OA: bronzeTopics (41)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Elentina K. Argyrousi ORCID,Ottavio Arancio ORCID,D. Martin Watterson ORCID,Saktimayee M. Roy ORCID,Erica Acquarone ORCID

Live enrichment

PubMed:38578894 PMC:PMC11091653 OpenAlex:https://openalex.org/W4393995902

NIA NIH HHS

Grant: U01 AG066722

NIA NIH HHS

Grant: P30 AG066462

National Institutes of Health

Grant: 3P30AG066462-01S1

Alzheimer's Disease Research Center Determinants of health seeking behaviors during COVID-19 in persons with MCI/ADRD and their caregivers

National Institutes of Health

Grant: 1U01AG066722-01

Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment

FWCI

2.23

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

bronzeLicense: CC BY NC

journalhttps://content.iospress.com:443/download/journal-of-alzheimers-disease/jad240063?id=journal-of-alzheimers-disease%2Fjad240063

publisherhttps://content.iospress.com:443/download/journal-of-alzheimers-disease/jad240063?id=journal-of-alzheimers-disease%2Fjad240063

publisherhttps://content.iospress.com/download?id=10.3233/JAD-240063

journalhttps://doi.org/10.3233/jad-240063

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38578894

Fields of Study

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesNeurotransmitter Receptor Influence on Behavior0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Alzheimer DiseaseAnimalsBrainDisease Models, AnimalHippocampusHumansMemory DisordersAmyloid beta-PeptidesLong-Term PotentiationReceptor, Serotonin, 5-HT2BSpatial Memory

Keywords

Long-term potentiationNeuroscienceAntagonistSynaptic plasticityPsychologyAlzheimer's diseaseDiseaseMedicineReceptorInternal medicineMemoryAlzheimer’s disease5Ht2b ReceptorMemory DisordersAmyloid beta-PeptidesBrainHippocampusDisease Models, AnimalAlzheimer DiseaseReceptor, Serotonin, 5-HT2BAnimalsHumansResearch ArticleSpatial Memory

Sustainable Development Goals

SDG 0: Good health and well-being